Short and long-term cytotoxicity investigations in stem cells for primary and secondary assays with an all- inclusive approach
International Conference on Toxicology and Pharmacology
November 01-02, 2017 | Toronto, Canada
Corina T Bot
Nanion Technologies, Germany
Scientific Tracks Abstracts : J Clin Exp Tox
In recent years, human stem cell-derived cardiomyocytes (hiPSC-CMs) have proven to represent a relevant human invitro system for modeling and interrogating complex biological processes, phenotypic profiles and disease models. Chip-based approaches allow parallel patch clamp recordings without compromising data quality or technical sophistication. We present high-throughput ion channel recordings in hiPSCCMs using Nanion’s automated patch clamping systems. The CardioExcyte 96 is a hybrid screening instrument that combines impedance with MEA-like extracellular field potential (EFP) recordings. In the light of the new Comprehensive . Proarrhythmia Assay (CiPA), a FDA directed initiative to improve guidelines and standardize assays and protocols, the use of hiPSCCMs may become critical in determining the proarrhythmic risk of potential drug candidates. In accordance with the CiPA guidelines, we present pharmacological investigations of short- and long-term effects of compounds from each risk category, in hiPSC-CMs. This approach strengthens the importance of testing compounds in assays complementary to patch clamp electrophysiology, to provide a more complete safety profile.
Corina T Bot obtained her PhD in Applied Physics from New Jersey Institute of Technology in 2010. Next, she worked for two years as a Post-doctoral Associate in Cardiology, at Cornell University, Weill Cornell Medical College. In her current position as a Senior Scientist at Nanion Technologies, she provides technical and scientific support for cell-based electrophysiology and toxicology assays, and automated patch clamp screening. Together with her colleagues at Nanion, she is participating in the FDA-directed Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to replace the preclinical hERG current assay required under the ICH S7B safety pharmacology guidelines and clinical TQT study.